Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates
Autore:
Casey, DE; Bruhwyler, J; Delarge, J; Geczy, J; Liegeois, JF;
Indirizzi:
Therabel Res, B-1180 Brussels, Belgium Therabel Res Brussels Belgium B-1180 rabel Res, B-1180 Brussels, Belgium Vet Adm Med Ctr, Div Mental Hlth, Portland, OR 97207 USA Vet Adm Med Ctr Portland OR USA 97207 Mental Hlth, Portland, OR 97207 USA Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA Oregon Reg Primate ResCtr Beaverton OR USA 97006 Beaverton, OR 97006 USA Univ Liege, Med Chem Lab, B-4000 Liege 1, Belgium Univ Liege Liege Belgium 1 Liege, Med Chem Lab, B-4000 Liege 1, Belgium Univ Liege, Physiol Lab, B-4020 Liege, Belgium Univ Liege Liege Belgium B-4020 iege, Physiol Lab, B-4020 Liege, Belgium
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 157, anno: 2001,
pagine: 228 - 235
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXTRAPYRAMIDAL SYNDROMES; INDUCED AGRANULOCYTOSIS; CLOZAPINE; DRUGS; PYRIDOBENZOXAZEPINE; NEUROLEPTICS; HALOPERIDOL; DERIVATIVES; DYSTONIA; MONKEYS;
Keywords:
JL 13; haloperidol; extrapyramidal side effect; non-human primate; serotonin; dopamine; clozapine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Geczy, J Therabel Res, 108 Rue Egide Van Ophem, B-1180 Brussels, Belgium Therabel Res 108 Rue Egide Van Ophem Brussels Belgium B-1180 ium
Citazione:
D.E. Casey et al., "The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates", PSYCHOPHAR, 157(3), 2001, pp. 228-235

Abstract

Rationale: Neuroleptic or antipsychotic drugs are the mainstay of treatingacute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. Objective: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. Methods: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPSof parkinsonism and dystonia, as well as reactivity. Results: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as aconsequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. Conclusions: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below thosethat can cause EPS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 19:10:32